According to the latest report by IMARC Group, titled “Premenstrual Syndrome Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027,” the global premenstrual syndrome treatment market is expected to exhibit a CAGR of XX% during 2022-2027.
Premenstrual syndrome (PMS) refers to a set of emotional, physical, and psychological symptoms that occur in women during the end of the luteal phase. It is caused by the elevated levels of progesterone and estrogen. Some of the common PMS symptoms include mood swings, breast tenderness, bloating, fatigue, anxiety, and body pain. PMS treatment involves various medications that help to increase the levels of serotonin hormone in the body. These treatments include analgesics, antidepressants, nonsteroidal anti-inflammatory drugs (NSAIDs), ovarian suppression agents, and hormonal contraceptives.
Request Free Sample Report: https://www.imarcgroup.com/premenstrual-syndrome-treatment-market/requestsample
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Market Trends:
The increasing prevalence of PMS and premenstrual dysphoric disorder (PMDD) is primarily driving the market growth. The rising awareness regarding the availability of alternative PMS treatment methods is further catalyzing the market growth. In line with this, pharmaceutical companies are investing in research and development (RD) activities to launch medications with minimal side-effects, which is contributing to the market growth. Additionally, the widespread adoption of plant-based nutritional supplements for PMS relief is presenting numerous growth opportunities to leading players in the market, thus creating a positive outlook for the market.
Breakup by Drug Type:
- Analgesics
- Antidepressants
- Oral Contraceptives and Ovarian Suppression Agents
- Others
Breakup by Type:
- Prescription
- Prescription
Breakup by Distribution Channel:
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Stores
Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Competitive Landscape with Key Player:
- AbbVie Inc
- BASF SE
- Bayer AG
- Dr. Reddy’s Laboratories Ltd
- Eli Lilly and Company
- GlaxoSmithKline Plc
- H. Lundbeck A/S
- Pfizer Inc
- SHIONOGI Co. Ltd
Ask Analyst for Customization and Explore Full Report with TOC List of Figure: https://www.imarcgroup.com/premenstrual-syndrome-treatment-market
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800